Form 6-K LakeShore Biopharma Co., For: Sep 22

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2025

 

Commission file number: 001-41598

 

 

LAKESHORE BIOPHARMA CO., LTD

 

(Exact name of registrant as specified in its charter)

 

 

Building No. 2, 38 Yongda Road

Daxing Biomedical Industry Park

Daxing District, Beijing, PRC

Tel: 010-89202086

(Address of Principal Executive Offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F  ☒          Form 40-F  ☐

 

 

 

EXHIBITS

 

Exhibit No.		Description
99.1		Press Release - LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	LakeShore Biopharma Co., Ltd
	By:	/s/ Rachel Yu
	Name:	Rachel Yu
	Title:	Director and Chief Financial Officer

 

Date: September 22, 2025

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE - LAKESHORE BIOPHARMA ANNOUNCES TRANSITION TO OTC MARKET FOLLOWING NASDAQ DELISTING

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nexbie 3D Printed Sneakers Review: Are They Worth Buying?
• Crypto News Today: BitMine’s 5.07M ETH Staking News Meets Apeing’s Crypto Presale Offering Up to 85% APY
• Apeing’s $0.0004 Presale Nears Its Next Stage: 410M+ Sold as Traders Eye the Next Big Crypto Beyond ETH and AVAX